B4GALNT1 Antibody

1. Data suggest that ganglioside glycosyltransferases ST3GAL5, ST8SIA1, and B4GALNT1 are S-acylated at conserved cysteine residues located close to cytoplasmic border of their transmembrane domains; ST3Gal-II is acylated at conserved cysteine residue in N-terminal cytoplasmic tail; for B4GALNT1 and ST3Gal-II, dimer formation controls their S-acylation status. PMID: 28698248
2. Novel B4GALNT1 mutations reported in two families with hereditary spastic paraplegia. PMID: 24283893
3. The resukts of this study identified mutations in B4GALNT1 (GM2 synthase), encoding the enzyme that catalyzes the second step in complex ganglioside biosynthesis, as the cause of this neurodegenerative phenotype. PMID: 24103911
4. Minimally disseminated disease in high risk retinoblastoma patients was detected using reverse transcriptase PCR for GD2 synthase mRNA in CSF. PMID: 23721779
5. Molecular upstaging of GalNAc-T using rt-pcr was correlated with prognosis in melanoma patients PMID: 21135695
6. GD2/GM2 is not a reliable biomarker in small cell lung carcinoma PMID: 19457569
7. The expression of three messengers coding for SAT-1, SAT-2 and GalNAcT-1 in human samples of intestinal cancer and some cell lines (breast cancer and melanomas), was evaluated. PMID: 17119850
8. Transmission disequilibrium test and case-control analysis did not detect an association of B4GALNT1 gene with T1DM. PMID: 19318031

Show More

Hide All

HGNC: 4117

OMIM: 601873

KEGG: hsa:2583

STRING: 9606.ENSP00000341562

UniGene: Hs.159481